Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Andrew Smith

Advertisement

Articles by Andrew Smith

Hypofractionation Emerges as Standard, but Not Yet for Every Patient

ByAndrew Smith
July 8th 2013

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivors⎯protocols that could greatly improve collective outcome.

  • Prev
  • 1
  • 2
  • Prev
Advertisement


Advertisement
Advertisement

Trending on OncLive

1

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

2

Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL

3

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

4

‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center

5

Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us